Arginine vasopressin is a peptide produced in the posterior pituitary whose primary physiologic role is fluid homeostasis. Recent investigations have demonstrated a therapeutic role for arginine vasopressin in adult cardiac arrest as well as adult and pediatric vasodilatory shock. We review the physiology of arginine vasopressin and examine the supporting data behind the developing clinical applications of this naturally produced peptide.
6. Lindner KH, Haak T, Keller A, Bothner U, Lurie KG.Release of endogenous vasopressors during and after cardiopulmonary resuscitation. Heart. 1996;75: 145-150.
7.
7. Brown CG, Taylor RB, Werman HA, Luu T, Ashton J, Hamlin RL.Myocardial oxygen delivery/consumption during cardiopulmonary resuscitation: a comparison of epinephrine and phenylephrine. Ann Emerg Med. 1988;17: 302-308.
8.
8. Tang W, Weil MH, Sun S, Noc M, Yang L, Gazmuri RJ.Epinephrine increases the severity of postresuscitation myocardial dysfunction. Circulation. 1995;92: 3089-3093.
9.
9. Lindner KH, Brinkmann A, Pfenninger EG, Lurie KG, Goertz A, Lindner IM.Effect of vasopressin on hemodynamic variables, organ blood flow, and acid-base status in a pig model of cardiopulmonary resuscitation. Anesth Analg. 1993;77: 427-435.
10.
10. Lindner KH, Prengel AW, Pfenninger EG, et al.Vasopressin improves vital organ blood flow during closed-chest cardiopulmonary resuscitation in pigs. Circulation. 1995;91: 215-221.
11.
11. Prengel AW, Lindner KH, Keller A.Cerebral oxygenation during cardiopulmonary resuscitation with epinephrine and vasopressin in pigs. Stroke. 1996;27: 1241-1248.
12.
12. Lindner KH, Prengel AW, Brinkmann A, Strohmenger H, Lindner IM, Lurie KG.Vasopressin administration in refractory cardiac arrest. Ann Intern Med. 1996;124: 1061-1064.
13.
13. Morris DC, Dereczyk BE, Brzybowski M, et al.Vasopressin can increase coronary perfusion pressure during human cardiopulmonary resuscitation. Acad Emerg Med. 1997;4: 878-883.
14.
14. Lindner KH, Dirks B, Strohmenger H, Prengel AW, Lindner IM, Lurie KG.Randomised comparison of epinephrine and vasopressin in patients with out-of-hospital ventricular fibrillation. Lancet. 1997;349: 535-537.
15.
15. Stiell IG, Hebert PC, Wells GA, et al.Vasopressin versus epinephrine for inhospital cardiac arrest: a randomized controlled trial. Lancet. 2001;358: 105-109.
16.
16. Wenzel V, Krismer AC, Arntz HR, Sitter H, Stadlbauer KH, Lindner KH.A comparison of vasopressin and epinephrine for out-of-hospital cardiopulmonary resuscitation. N Engl J Med. 2004;350: 1005-1013.
17.
17. Voelckel WG, Lurie KG, McKnite S, et al.Comparison of epinephrine and vasopressin in a pediatric porcine model of asphyxial cardiac arrest. Crit Care Med. 2000;28: 3777-3783.
18.
18. Voelckel W, Lurie K, McKnite S, et al.Effects of epinephrine and vasopressin in a pediatric porcine model of ventricular fibrillation. Crit Care Med. 2000;28: A68.
19.
19. Mann K, Berg RA, Nadkarni V.Beneficial effects of vasopressin in prolonged pediatric cardiac arrest: a case series. Resuscitation. 2002;52: 149-156.
20.
20. Landry DW, Levin HR, Gallant EM, et al.Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation. 1997;95: 1122-1125.
21.
21. Argenziano M, Chen JM, Choudhri AF, et al.Management of vasodilatory shock after cardiac surgery: identification of predisposing factors and use of a novel pressor agent. J Thorac Cardiovasc Surg. 1998;116: 973-980.
22.
22. Tsuneyoshi I, Yamada H, Kakihana Y, Nakamura M, Nakano Y, Boyle WA III.Hemodynamic and metabolic effects of low-dose vasopressin infusions in vasodilatory septic shock. Crit Care Med. 2001;29: 487-493.
23.
23. Landry DW, Levin HR, Gallant EM, et al.Vasopressin pressor hypersensitivity in vasodilatory septic shock. Crit Care Med. 1997;25: 1279-1282.
24.
24. Argenziano M, Choudhri AF, Oz MC, Rose EA, Smith CR, Landry DW.A prospective randomized trial of arginine vasopressin in the treatment of vasodilatory shock after left ventricular assist device placement. Circulation. 1997;96(suppl 2): 286-290.
25.
25. Malay MB, Ashton RC, Landry DW, Townsend RN.Lowdose vasopressin in the treatment of vasodilatory septic shock. J Trauma. 1999;47: 699-705.
26.
26. Argenziano M, Chen JM, Cullinane S, et al.Arginine vasopressin in the management of vasodilatory hypotension after cardiac transplantation. J Heart Lung Transplant. 1999;18: 814-817.
27.
27. Morales DLS, Gregg D, Helman DN, et al.Arginine vasopressin in the treatment of 50 patients with postcardiotomy vasodilatory shock. Ann Thorac Surg. 2000;69: 102-106.
28.
28. Bracco D, Chiolero BD, Revelly JP.Systemic and splanchnic haemodynamic effects of vasopressin administration in vasodilatory shock [abstract]. Intensive Care Med. 2001;27(suppl 2): A15.
29.
29. Dunser MW, Mayr AJ, Ulmer H, et al.The effects of vasopressin on systemic hemodynamics in catecholamineresistant septic and postcardiotomy shock: a retrospective analysis. Anesth Analg. 2001;23: 7-13.
30.
30. Holmes CL, Waller KR, Chittock DR, Lehman T, Russell JA.The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series. Intensive Care Med. 2001;27: 1416-1421.
31.
31. Dunser MW, Mayr AJ, Stallinger A, et al.Cardiac performance during vasopressin infusion in postcardiotomy shock. Intensive Care Med. 2002;28: 746-751.
32.
32. Dunser MW, Mayr AJ, Ulmer H, et al.Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation. 2003;107: 2313-2319.
33.
33. Rosenzweig EB, Starc TJ, Chen JM, et al.Intravenous arginine-vasopressin in children with vasodilatory shock after cardiac surgery. Circulation. 1999;100(suppl 2): 182-186.
34.
34. Katz K, Lawler J, Wax J, O’Connor R, Nadkarni V.Vasopressin pressor effects in critically ill children during evaluation for brain death and organ recovery. Resuscitation. 2000;47: 33-40.
35.
35. Starc TJ, Rosenzweig EB, Landry DW, et al.Emergency use of vasopressin in children with vasodilatory shock due to sepsis or after bypass. Crit Care Med. 2000;28: A71.
36.
36. Liedel JL, Meadow W, Nachman J, Koogler T, Kahana MD.Use of vasopressin in refractory hypotension in children with vasodilatory shock: five cases and a review of the literature. Pediatr Crit Care Med. 2002;3: 15-18.
37.
37. Tobias JD.Arginine vasopressin for refractory distributive shock in two adolescents. J Intensive Care Med. 2002;17: 48-52.
38.
38. Dunser MW, Mayr AJ, Tr A, et al.Ischemic skin lesions as a complication of continuous vasopressin infusion in catecholamine-resistant vasodilatory shock: incidence and risk factors. Crit Care Med. 2003;31: 1394-1398.
39.
39. Leather HA, Eng PS, Berends N, Vandermeersch E, Wouters PF.Effects of vasopressin on right ventricular function in an experimental model of acute pulmonary hypertension. Crit Care Med. 2002;30: 2548-2552.
